Clinical Trial Update: Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of V116 in pneumococcal vaccine-naïve adults has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infection | Phase 3 | Status: COMPLETED | Results posted: 2024-06-10